Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC.
Journal
Future oncology (London, England)
Journal Volume
21
Journal Issue
17
ISSN
1744-8301
Date Issued
2025-07
Author(s)
Abstract
Background: The clinical characteristics and outcomes of younger versus older patients with EGFR-mutated advanced NSCLC undergoing first-line EGFR-TKI treatment remain underexplored. Methods: This multicenter, retrospective study analyzed patients treated between 2010 and 2019. Univariate and multivariate analyses identified factors associated with outcomes. Results: Among 235 patients, 38 were under 50 years and 197 over 65 years. Median progression-free survival (PFS) was 21.1 months in younger patients and 15.6 months in older patients (p = 0.095). Median overall survival (OS) was 40.0 months in the young group and 23.2 months in the elderly group (p = 0.008). Afatinib or erlotinib was linked to longer OS in younger patients. In elderly patients, better ECOG performance status and body mass index over 18.5 were significantly associated with improved OS. Conclusion: Younger patients receiving afatinib or erlotinib showed better outcomes. For older patients, clinical factors such as functional status and body weight strongly influenced survival.
Subjects
ECOG performance status
EGFR
NSCLC
TKI
Taiwan
afatinib and erlotinib
multicenter study
young age
Type
journal article